Platelet dense-granule secretion plays a critical role in thrombosis and subsequent vascular remodeling in

Sarah M King1, Rachel A McNamee, Aiilyan K Houng

  • 1Cardiovascular Biology, Harvard School of Public Health, Boston, Mass, USA.

Circulation
|August 19, 2009
PubMed

Insights

Reduced platelet dense-granule secretion significantly protects against arterial thrombosis, inflammation, and neointimal hyperplasia in atherosclerosis-prone mice. This finding highlights the role of platelet secretion in vascular disease progression.

Area of Science:

  • Cardiovascular Biology
  • Hematology
  • Immunology

Background:

  • Platelet aggregation is crucial in myocardial infarction and stroke.
  • The role of platelet secretion in atherosclerotic vascular disease remains unclear.
  • Platelet dense-granule secretion's impact on thrombosis, inflammation, and vascular remodeling requires investigation.

Purpose of the Study:

  • To investigate the role of platelet dense-granule secretion in modulating thrombosis, inflammation, and atherosclerotic vascular remodeling after injury.
  • To test the hypothesis that reduced platelet dense-granule secretion confers protection against vascular disease progression.

Main Methods:

  • Utilized Hermansky-Pudlak syndrome 3 gene deficient (HPS3(-/-)) mice to reduce platelet dense-granule secretion.
  • Compared atherosclerosis-prone mice with and without HPS3 deficiency (ApoE(-/-), HPS3(-/-) vs. ApoE(-/-), HPS3(+/+)) after high-fat diet.
  • Assessed arterial thrombosis, neointimal hyperplasia, and inflammation following carotid artery injury (FeCl3).

Main Results:

  • HPS3(-/-) mice exhibited markedly reduced platelet dense-granule secretion but normal alpha-granule secretion and platelet counts.
  • ApoE(-/-), HPS3(-/-) mice were resistant to FeCl3-induced arterial thrombosis.
  • Reduced neointimal hyperplasia and significant decreases in arterial leukocytes and macrophages were observed in ApoE(-/-), HPS3(-/-) mice post-injury.

Conclusions:

  • Reduced platelet dense-granule secretion is associated with significant protection against arterial thrombosis in a mouse model of atherosclerosis.
  • Diminished platelet secretion also confers protection against post-injury inflammation and neointimal hyperplasia.
  • Platelet dense-granule secretion is a key factor in the development of vascular disease complications.
Abstract

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...